Medical Access Program for Ifinatamab Deruxtecan in 3L+ Pretreated Extensive-stage Small Cell Lung Cancer
Daiichi Sankyo
Daiichi Sankyo
Nuvalent Inc.
Aveni Foundation
Nuvalent Inc.
AbbVie
AbbVie
xCures
Second Life Therapeutics
Agenus Inc.
Xcovery Holdings, Inc.
Shandong Cancer Hospital and Institute